These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 32300130)

  • 1. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile.
    Phanchana M; Phetruen T; Harnvoravongchai P; Raksat P; Ounjai P; Chankhamhaengdecha S; Janvilisri T
    Sci Rep; 2020 Apr; 10(1):6497. PubMed ID: 32300130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.
    Roder C; Athan E
    Drugs R D; 2020 Sep; 20(3):209-216. PubMed ID: 32377889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin inhibits spore production in Clostridium difficile.
    Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
    James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS
    J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile.
    Wultańska D; Piotrowski M; Pituch H
    Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1391-1399. PubMed ID: 32140903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
    Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of
    Bassères E; Eubank TA; Begum K; Alam MJ; Jo J; Le TM; Lancaster CK; Gonzales-Luna AJ; Garey KW
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0162123. PubMed ID: 38364016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
    Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
    PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
    Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
    Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections.
    Abutaleb NS; Seleem MN
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253206
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences.
    Kolte B; Nübel U
    J Antimicrob Chemother; 2024 Jun; 79(6):1320-1328. PubMed ID: 38598696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile.
    Hamada M; Yamaguchi T; Ishii Y; Chono K; Tateda K
    J Infect Chemother; 2020 Jul; 26(7):685-692. PubMed ID: 32224190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
    Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile.
    Pu M; Cho JM; Cunningham SA; Behera GK; Becker S; Amjad T; Greenwood-Quaintance KE; Mendes-Soares H; Jones-Hall Y; Jeraldo PR; Chen J; Dunny G; Patel R; Kashyap PC
    Gastroenterology; 2021 Feb; 160(3):941-945.e8. PubMed ID: 33197449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection.
    Abutaleb NS; Seleem MN
    Sci Rep; 2020 May; 10(1):7701. PubMed ID: 32382070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing the Veterinary Antiprotozoal Drug Ronidazole for the Treatment of Clostridioides difficile Infection.
    AbdelKhalek A; Seleem MN
    Int J Antimicrob Agents; 2020 Dec; 56(6):106188. PubMed ID: 33045352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress on mechanisms of antibiotic resistance in Clostridioides difficile.
    Xu T; Huang HH
    Yi Chuan; 2023 Nov; 45(11):1028-1038. PubMed ID: 38764268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.
    Abujamel T; Cadnum JL; Jury LA; Sunkesula VC; Kundrapu S; Jump RL; Stintzi AC; Donskey CJ
    PLoS One; 2013; 8(10):e76269. PubMed ID: 24098459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.